We are live on !
Find out more
Broadfin Capital Portfolio holdings
AUM
$747M
Turnover
50.88%
1-Year Est. Return
100.56%
This Fund
S&P 500
This Quarter Est. Return
+6.13%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$6.85M
(-0.66%)
Cap. Flow
+$37.9M
Cap. Flow % of AUM
Cap. Flow %
3.69%
Top 10 Holdings %
Top 10 Hldgs %
54.01%
Holding
84
New
13
Increased
14
Reduced
14
Closed
14
Avg Time Held
Equity + Options
1.6
years
Top 10 Avg Time Held
Equity + Options
1.1
years
Top 20 Avg Time Held
Equity + Options
1
year
Avg Time Held Equity only
1.6
years
Top 10 Avg Time Held Equity only
1.2
years
Top 20 Avg Time Held Equity only
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ENDP
Endo International
ENDP
|
+$21.3M |
| 2 |
AngioDynamics
ANGO
|
+$13.9M |
| 3 |
XENT
Intersect ENT
XENT
|
+$11.1M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$9.01M |
| 5 |
ISEE
IVERIC bio
ISEE
|
+$8.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nevro
NVRO
|
+$18.7M |
| 2 |
XNPT
XenoPort
XNPT
|
+$7.18M |
| 3 |
PTX
Pernix Therapeutics Holdings
PTX
|
+$6.4M |
| 4 |
ELOS
Syneron Medical
ELOS
|
+$6.36M |
| 5 |
ANAC
Anacor Pharmaceuticals
ANAC
|
+$5.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.13% |
| 2 | Miscellaneous | 16.76% |
| 3 | Technology | 0.11% |
Similar funds
SC
LB
Broadfin Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Broadfin Capital held 84 positions worth $1.03B, down 0.66% from $1.04B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Broadfin Capital deployed $37.9M of net new capital in Q2 2016, opening 13 new positions and adding to 14 existing holdings. Its largest new stake was Endo International: 1,028,802 shares worth $16M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was Nevro, an estimated $18.7M trimmed.
- Broadfin Capital's largest Q2 2016 buy was Endo International: 1,028,802 shares worth $16M.
- Broadfin Capital added most to AngioDynamics in Q2 2016, an estimated $13.9M increase.
- Broadfin Capital's biggest Q2 2016 reduction was Nevro, cutting an estimated $18.7M.
- Broadfin Capital fully exited XenoPort in Q2 2016, selling an estimated $7.18M.
- Broadfin Capital's ten largest holdings make up 54% of its $1.03B portfolio in Q2 2016.
- Broadfin Capital opened 13 new positions and closed 14 in Q2 2016.
- Broadfin Capital's portfolio value fell 0.66% quarter-over-quarter to $1.03B.
Based on Broadfin Capital's 13F filing for Q2 2016, filed 15 Aug 2016.